FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792519959> ?p ?o ?g. }

• W2792519959 endingPage "524" @default.
• W2792519959 startingPage "519" @default.
• W2792519959 abstract "ABSTRACT Purpose: Postoperative vasoplegic shock after cardiac surgery seems to be a frequent complication with poor outcomes. We hypothesized that vasopressin may increase the risk of poor outcomes in patients with preoperative Left Ventricular Dysfunction (pLVD) rather than norepinephrine. The aim of this study was to assess whether vasopressin is superior to norepinephrine to improve outcomes in patients with pLVD after cardiac surgery. Methods: This retrospective cohort study included 1,156 patients with postoperative vasoplegic shock (mean arterial pressure <65 mmHg resistant to fluid challenge and cardiac index >2.20 L/min m 2 ) and pLVD (left ventricular ejection fraction ≤35%, left ventricular end-diastolic diameter ≥60 mm, New York Heart Association ≥III) from 2007 to 2017. To address any indicated biases, we derived a propensity score predicting the functions of vasopressin (0.02–0.07 U/min) and norepinephrine (10–60 μg/min) on postoperative vasoplegic shock. The primary outcomes were 30-day mortality, mechanical ventilation more than 48 h, cardiac reoperation, extracorporeal membrane oxygenation, stroke, and acute kidney injury, whereas the secondary outcomes included infection, septic shock, atrial fibrillation and ventricular arrhythmias. Results: There were 338 patients (169 vasopressin and169 norepinephrine) with a similar risk profile in propensity score-matched cohort. In propensity-matched patients, the primary outcomes of vasopressin and norepinephrine showed no significant difference (50.89% vs. 58.58%, P = 0.155). However, compared with norepinephrine, secondary outcomes of vasopressin were increased due to the high rate of atrial fibrillation (11.83% vs. 20.12%, P = 0.038) and ventricular arrhythmias (14.20% vs. 24.85%, P = 0.014). Conclusions: Compared with norepinephrine, vasopressin could not improve the postoperative outcomes in patients with pLVD after cardiac surgery. Vasopressin should be cautious to be used as a first-line vasopressor agent in postcardiac vasoplegic shock." @default.
• W2792519959 created "2018-03-29" @default.
• W2792519959 creator A5008986678 @default.
• W2792519959 creator A5010589629 @default.
• W2792519959 creator A5011830721 @default.
• W2792519959 creator A5024818901 @default.
• W2792519959 creator A5026798878 @default.
• W2792519959 creator A5041529308 @default.
• W2792519959 creator A5055669256 @default.
• W2792519959 creator A5059343029 @default.
• W2792519959 creator A5062752842 @default.
• W2792519959 creator A5064548129 @default.
• W2792519959 date "2018-11-01" @default.
• W2792519959 modified "2023-09-25" @default.
• W2792519959 title "Evaluation of Vasopressin for Vasoplegic Shock in Patients With Preoperative Left Ventricular Dysfunction After Cardiac Surgery: A Propensity-Score Analysis" @default.
• W2792519959 cites W1967300023 @default.
• W2792519959 cites W2002926363 @default.
• W2792519959 cites W2003315388 @default.
• W2792519959 cites W2007790231 @default.
• W2792519959 cites W2012448208 @default.
• W2792519959 cites W2062054105 @default.
• W2792519959 cites W2090026174 @default.
• W2792519959 cites W2094412782 @default.
• W2792519959 cites W2108153775 @default.
• W2792519959 cites W2110944531 @default.
• W2792519959 cites W2128042478 @default.
• W2792519959 cites W2156202966 @default.
• W2792519959 cites W2164789454 @default.
• W2792519959 cites W2168840607 @default.
• W2792519959 cites W2322971667 @default.
• W2792519959 cites W2553631662 @default.
• W2792519959 cites W4296024375 @default.
• W2792519959 doi "https://doi.org/10.1097/shk.0000000000001114" @default.
• W2792519959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29424795" @default.
• W2792519959 hasPublicationYear "2018" @default.
• W2792519959 type Work @default.
• W2792519959 sameAs 2792519959 @default.
• W2792519959 citedByCount "15" @default.
• W2792519959 countsByYear W27925199592018 @default.
• W2792519959 countsByYear W27925199592019 @default.
• W2792519959 countsByYear W27925199592020 @default.
• W2792519959 countsByYear W27925199592021 @default.
• W2792519959 countsByYear W27925199592023 @default.
• W2792519959 crossrefType "journal-article" @default.
• W2792519959 hasAuthorship W2792519959A5008986678 @default.
• W2792519959 hasAuthorship W2792519959A5010589629 @default.
• W2792519959 hasAuthorship W2792519959A5011830721 @default.
• W2792519959 hasAuthorship W2792519959A5024818901 @default.
• W2792519959 hasAuthorship W2792519959A5026798878 @default.
• W2792519959 hasAuthorship W2792519959A5041529308 @default.
• W2792519959 hasAuthorship W2792519959A5055669256 @default.
• W2792519959 hasAuthorship W2792519959A5059343029 @default.
• W2792519959 hasAuthorship W2792519959A5062752842 @default.
• W2792519959 hasAuthorship W2792519959A5064548129 @default.
• W2792519959 hasBestOaLocation W27925199591 @default.
• W2792519959 hasConcept C126322002 @default.
• W2792519959 hasConcept C139940330 @default.
• W2792519959 hasConcept C164705383 @default.
• W2792519959 hasConcept C178853913 @default.
• W2792519959 hasConcept C17923572 @default.
• W2792519959 hasConcept C2776370428 @default.
• W2792519959 hasConcept C2776858399 @default.
• W2792519959 hasConcept C2778198053 @default.
• W2792519959 hasConcept C2778514916 @default.
• W2792519959 hasConcept C2781005686 @default.
• W2792519959 hasConcept C2781300812 @default.
• W2792519959 hasConcept C31861589 @default.
• W2792519959 hasConcept C42219234 @default.
• W2792519959 hasConcept C513476851 @default.
• W2792519959 hasConcept C71924100 @default.
• W2792519959 hasConcept C78085059 @default.
• W2792519959 hasConcept C80461066 @default.
• W2792519959 hasConceptScore W2792519959C126322002 @default.
• W2792519959 hasConceptScore W2792519959C139940330 @default.
• W2792519959 hasConceptScore W2792519959C164705383 @default.
• W2792519959 hasConceptScore W2792519959C178853913 @default.
• W2792519959 hasConceptScore W2792519959C17923572 @default.
• W2792519959 hasConceptScore W2792519959C2776370428 @default.
• W2792519959 hasConceptScore W2792519959C2776858399 @default.
• W2792519959 hasConceptScore W2792519959C2778198053 @default.
• W2792519959 hasConceptScore W2792519959C2778514916 @default.
• W2792519959 hasConceptScore W2792519959C2781005686 @default.
• W2792519959 hasConceptScore W2792519959C2781300812 @default.
• W2792519959 hasConceptScore W2792519959C31861589 @default.
• W2792519959 hasConceptScore W2792519959C42219234 @default.
• W2792519959 hasConceptScore W2792519959C513476851 @default.
• W2792519959 hasConceptScore W2792519959C71924100 @default.
• W2792519959 hasConceptScore W2792519959C78085059 @default.
• W2792519959 hasConceptScore W2792519959C80461066 @default.
• W2792519959 hasIssue "5" @default.
• W2792519959 hasLocation W27925199591 @default.
• W2792519959 hasLocation W27925199592 @default.
• W2792519959 hasLocation W27925199593 @default.
• W2792519959 hasOpenAccess W2792519959 @default.
• W2792519959 hasPrimaryLocation W27925199591 @default.
• W2792519959 hasRelatedWork W1965118241 @default.
• W2792519959 hasRelatedWork W2000660106 @default.
• W2792519959 hasRelatedWork W2037104730 @default.

• next